The FY 2022 Sequoia Financial Groups results show revenue up but earnings per share quite flat as the company invests in future growth.

The FY 2022 Australian Ethical Investments results show profit down as a result of increased spending for future growth.

The FY 2022 Ebos Group results show a decent defensive dividend stock, but ongoing capital investment will be required for growth.

The FY 2022 Nanosonics results show revenue growth but net profit lower, due to building out the direct sales function.

The FY 2022 Camplify results show a business that is bringing more people to both sides of its campervan hiring platform. However, the headline revenue growth is not the best measure.

The FY 2022 Energy One Results show a year of potentially transformational investment as it focuses on growing its 24/7 energy dispatching services business.

The Janison (ASX: JAN) FY 2022 results scorecard is filled so with some green ticks but there are more red crosses, here’s why.

The FY 2022 Codan results were pretty much flat year on year, but that is not a bad result, coming off a bumper year in FY 2021.

PWR (ASX: PWH) FY22 results demonstrate why PWR is considered to be one of the highest quality growth stocks on the ASX. Price remains the barrier.

Fintwit favourite PTB Group (ASX: PTB) has received a takeover offer… and beaten its guidance!

The FY 2022 Data#3 (ASX: DTL) results showed strong revenue growth but gross profit margins heading in the wrong direction.

Pro Medicus results show record revenue and profit in FY 2022. Is the Pro Medicus (ASX: PME) competitive advantage improving?

The FY 2022 Nearmap results showed revenue up 29% but a net loss increased by 64%. Of course, it also has a takeover offer.

These results suggest Temple and Webster (ASX: TPW) is one of the more resilient online retailers, listed on the ASX.

With a new CEO, the acquisition of Guildlink, and the forecast that it will be “breakeven at an earnings level in FY23,” MedAdvisor is pointing to brighter days ahead.

But what are the risks?

Multibaggers like ResMed (ASX: RMD), Cochlear (ASX: COH) and PWR Holdings (ASX: PWH) are prior winners of the Australian Export Awards.

Audinate (ASX: AD8) and Objective Corporation (ASX: OCL) could be considered high quality growth stocks, but they have a price tag to match.

A candidate for an inverse ESG portfolio, Farm Pride Foods (ASX: FRM) might be not be deep value, but rather, a deep value trap…

These two med-tech stocks are still fairly high risk, but they are approaching the profitability inflection point, and have long term tailwinds supporting the businesses.

I thought Diverger (ASX: DVR) would pay increasing dividends but the in company’s unaudited earnings presentation didn’t mention dividends.